Surovatamig Clinical Trials
6 recruitingDrug
Phase 23Phase 32Phase 12
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 3
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca420 enrolled30 locationsNCT07509151
Recruiting
Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled193 locationsNCT06549595
Recruiting
Phase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Primary Membranous Nephropathy
AstraZeneca43 enrolled21 locationsNCT07571746
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Phase 1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Rheumatoid ArthritisSystemic Lupus Erythematosus
AstraZeneca48 enrolled19 locationsNCT07201558